Trafalgar International (GCAN) Interest & Investment Income (2018 - 2019)
Greater Cannabis Company (GCAN) posted quarterly Interest & Investment Income of -$3972.0 for Q3 2019, up 72.64% year-over-year from -$2300.8 in Q3 2018, and up 72.64% quarter-over-quarter from -$14515.0 in Q3 2018.
Trafalgar International (GCAN) Interest & Investment Income (2018 - 2019) Analysis & Trends
Greater Cannabis Company's Interest & Investment Income history runs 2 years deep, the most recent figure standing at -$3972.0 for Q3 2019.
- In Q3 2019, Interest & Investment Income rose 72.64% year-over-year to -$3972.0; the TTM figure through Sep 2019 stood at -$18487.0 (changed N/A YoY), while the FY2018 annual figure was $5903.0, changed N/A from the prior year.
- Interest & Investment Income for Q3 2019 stood at -$3972.0, up from -$14515.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $5903.0 in Q1 2018, with the low at -$14515.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -3,972.00 |
| Sep 30, 2018 | -14,515.00 |
| Mar 31, 2018 | 5,903.00 |